Moolec Science Stock Price, News & Analysis

Moolec Science (NASDAQ:MLEC) announced a 15-for-1 share consolidation of its ordinary shares, effective at 8:00 a.m. ET on January 5, 2026. The consolidation will change par value from US$0.10 to US$1.50 per share and reduce issued and outstanding shares from 10,891,761 to approximately 726,118. Fractional shares will be rounded up to whole shares; no fractional share certificates will be issued. The consolidated shares will begin trading on Nasdaq Capital Market under CUSIP G6223S125 upon market open on January 5, 2026. The company says the Share Consolidation is intended to regain compliance with Nasdaq's minimum bid price rule (Rule 5550(a)(2)).

Moolec Science (NASDAQ:MLEC) announced completion of its 2025 U.S. GLASO1 safflower campaign, marking its first large-scale deployment of a plant-engineered molecular farming platform.

Key outcomes: 1,100 acres cultivated, average yield ~2,200 lb/acre versus 1,400 lb/acre in 2024 (a 57.1% YoY increase), and acreage expanded by more than 100% versus prior cycles. The company says harvests exceeded internal forecasts and validated large-volume harvest management, traceability, and quality controls.

Moolec plans to enter the U.S. nutrition and supplements market and pursue high-concentration GLA softgel applications to access premium channels and recurring demand.

Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 24, 2025, stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) for failing to file its Annual Report on Form 20-F for year ended June 30, 2025 with the SEC.

The company attributed the delay to post-closing complexities from a mid-June 2025 business combination that triggered reverse acquisition accounting and valuation work. Moolec filed a Form 12b-25 on October 31, 2025, and requested a stay of suspension; the stay remains in effect pending a Nasdaq Hearings Panel hearing scheduled for December 18, 2025. Ordinary shares will continue trading on The Nasdaq Capital Market under the symbol MLEC during the stay. The company expects to file the Form 20-F before the hearing.

Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 14, 2025, notifying the company that its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).

The letter indicated Nasdaq's view that the company would not receive an automatic 180-day compliance period. Moolec submitted a timely appeal to a Nasdaq Hearings Panel and requested a 180-day period to file and implement a compliance plan, which may include a reverse stock split if in shareholders' best interest.

The appeal automatically stays the determination until the hearing on December 18, 2025, and the company's ordinary shares will continue to trade as MLEC during the stay. The company said the letter does not affect its business operations or SEC reporting obligations.

Moolec Science (NASDAQ:MLEC), a biotechnology company focused on engineering plants and microbes for protein solutions, announced three significant developments. First, the company received regulatory approval from SENASA in Argentina for its safflower GLASO technology, enabling expansion of its GLA-enriched safflower crop production. Second, Moolec has doubled its U.S. safflower acreage compared to last year, strengthening its supply capabilities for the pet food and human nutrition markets.

Additionally, the company appointed Valeria Falottico as CFO, bringing over 20 years of financial expertise. Moolec also completed the integration of Mycofood™, its fungal-based protein platform, which is currently developing products for evaluation by food industry partners in North America and Europe.

Moolec Science (NASDAQ:MLEC) has secured a crucial U.S. patent for its Piggy Sooy™ technology, a groundbreaking soybean engineered to produce high levels of porcine hemeproteins in seeds. The patent, valid until 2042, covers plants, seeds, development methods, and derived food compositions. Initial field trials showed impressive results with over 20% animal protein content in the total soluble protein fraction. The technology demonstrates significant environmental advantages: one acre of Piggy Sooy™ can produce protein equivalent to 10 pigs while using 35x less land, 8x less water, and generating 60x less CO2 emissions. The USDA-APHIS has already confirmed the technology poses no additional plant pest risk compared to conventional soybeans, marking a key milestone toward commercialization. This patent is part of Moolec's broader strategy, with over fifteen global patent applications protecting their Molecular Farming innovations.

Moolec Science (NASDAQ:MLEC) has successfully completed a strategic business combination with Bioceres Group, Gentle Technologies Corp, and Nutrecon LLC. The merger was approved by shareholders with 98% of votes in favor. Under the deal terms, Bioceres Group shareholders received ~6.9M Moolec shares, while Nutrecon and Gentle Tech shareholders got ~0.65M shares and 0.5M private warrants at $20 strike price. The company appointed Alejandro Antalich as CEO, bringing 20+ years of biotech leadership experience. The combined entity maintains the Moolec Science name and NASDAQ listing (MLEC, MLECW). This merger expands Moolec's capabilities across food ingredients, ag-biologicals, precision fermentation, and biomaterials, integrating products like Piggy Sooy, GLASO, Mycofood, and biological inputs under brands including Rizobacter, ProFarm, and HB4.

Moolec Science (NASDAQ:MLEC) has announced the implementation of a 1-for-10 reverse stock split, effective May 14, 2025, at 8:30 AM Eastern Time. The consolidation will reduce the company's outstanding shares from approximately 40 million to 4 million shares, with no change to the par value per share. The stock will continue trading on NASDAQ under the symbol "MLEC" with a new CUSIP code (L64875 120), while warrants will maintain their "MLECW" symbol. Shareholders are not required to take any action, as positions will be automatically adjusted. The reverse split follows resolutions passed at the extraordinary general meeting and board meeting on April 22, 2025.

Moolec Science (NASDAQ:MLEC) has announced a transformational all-stock Business Combination Agreement with Bioceres Group and other entities. The deal involves Moolec issuing up to 87 million new shares and 5 million warrants to acquire Bioceres Group, Nutrecon , and Gentle Technologies Corp.

The combined entity will control a portfolio of over 800 patents and 550 product registrations, representing more than half a billion dollars in annual sales across 50+ countries. The transaction positions Moolec as a comprehensive agricultural technology company, integrating molecular farming, biological inputs, and climate-resilient seeds.

Key highlights include:

• Continued development of molecular farming products (Piggy Sooy™, GLASO™)
• Integration of biological agricultural solutions through Bioceres Group
• Expansion into R&D and CDMO services under Agrality® and Synbio Powerlabs®
• Development of emerging technologies in biomaterials and farm equipment

The transaction is expected to close in Q2 2025, subject to shareholder approval and other conditions. CEO Gastón Paladini will step down following the April 22, 2025 Extraordinary General Meeting.